Krystal Biotech Expects FDA Meeting on KB111 in Q1 2027
The company expects to meet with the FDA to discuss study results and designs intended to enable a registrational study start in 2027.
Related stories
Marvell to Acquire Lumentum in Major Deal
Reuters reports that Marvell will acquire Lumentum. Deal terms were not provided.
M impact | EQUITY | Nov 02, 2026, 01:37 PM UTC
CTT shares fall 4.7% to lowest since December 2024
M impact | EQUITY | Nov 02, 2026, 01:24 PM UTC
Xcel Energy gibt nach Plänen für Wandelanleihe über 2 Milliarden US-Dollar nach
Xcel Energy-Aktien gaben nach Bekanntgabe von Plänen für eine Wandelanleihe im Wert von 2 Milliarden US-Dollar nach.
M impact | EQUITY | Nov 02, 2026, 01:24 PM UTC
Xcel Energy shares dip after unveiling $2 billion convertible offering plans
Xcel Energy shares dipped after the company unveiled plans for a $2 billion convertible offering.
M impact | EQUITY | Nov 02, 2026, 01:24 PM UTC
Innventure Forms Strategic Review Committee and Cuts Headcount to 15
Innventure formed a committee to review capital strategies as it cuts costs and addresses near-term parent-company liquidity needs.
M impact | EQUITY | Nov 02, 2026, 01:23 PM UTC
Marriott CEO Says Caribbean RevPAR Fueled by Luxury and Leisure Demand
Marriott’s CEO said strong luxury and leisure demand across the Caribbean is driving regional RevPAR, offsetting continued softness in Mexico.
M impact | EQUITY | Nov 02, 2026, 01:22 PM UTC